Search results for " transplantation."

showing 10 items of 1389 documents

Leishmaniasis among organ transplant recipients.

2008

Leishmaniasis is a rarely reported disease among transplant recipients; however, the number of published cases has quadrupled since the beginning of the 1990s. Most cases have been observed in patients living in countries of the Mediterranean basin. Leishmaniasis is most commonly associated with kidney transplantation (77%), and cases are also recorded among patients undergoing liver, heart, lung, pancreas, and bone marrow transplantation. Visceral leishmaniasis (VL) is the most frequently observed clinical presentation, followed by mucosal leishmaniasis and more rarely cutaneous leishmaniasis. Transplant recipients with VL develop the classic clinical form of the disease, which is a febril…

medicine.medical_specialtybusiness.industryMediterranean RegionIncidence (epidemiology)LeishmaniasisDiseaseOrgan Transplantationmedicine.diseaseOrgan transplantationTransplantationInfectious DiseasesVisceral leishmaniasisCutaneous leishmaniasisInternal medicineImmunologymedicineHumansLeishmaniasis VisceralbusinessLeishmaniasisKidney transplantationThe Lancet. Infectious diseases
researchProduct

Halitosis, reduced salivary flow and the quality of life in pre-kidney transplantation patients

2020

Background Halitosis is a condition that affects 50% of adults and one third of patients with chronic kidney disease. The aim of this study was to evaluate oral manifestations and volatile sulfur compounds (VSCs) associated with halitosis and quality of life in pre-kidney transplantation candidates. Material and Methods The organoleptic test (OT) and halimetry (HA) (before and after cysteine mouthwash) were performed in patients with the Oralchroma® device, stimulated (SE) and non-stimulated sialometry (SN), Tongue Coating Index (TCI). The OHIP-14 questionnaire was administered to assess the impact of oral health on quality of life. Results Fourteen individuals with a mean age of 49.64 ± 13…

medicine.medical_specialtybusiness.industryResearchNEFROPATIASMean ageOral health:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseGastroenterologyTransplantationQuality of lifeInternal medicineUNESCO::CIENCIAS MÉDICASmedicineOdontostomatology for the Disabled or Special PatientsIn patientTongue coatingbusinessGeneral DentistryKidney transplantationKidney diseaseJournal of Clinical and Experimental Dentistry
researchProduct

Assoziation einer arteriellen Verschlußkrankheit mit Ciclosporin-Therapie nach Nierentransplantation

2008

Renal transplantation followed by immunosuppression with cyclosporine (whole-blood levels 200-300 micrograms/l) and methylprednisolone (4 mg daily) was performed in a 54-year-old man with chronic glomerulonephritis. Three years later rapidly progressive arterial obstructive disease (peripheral type) developed. Parenteral treatment with prostaglandins, calcium antagonists and nitrates, as well as a lumbar sympathectomy, was unsuccessful so that, in rapid succession, several amputations on upper and lower limbs became necessary. The disease progression was arrested only when azathioprine replaced cyclosporine. Raynaud's phenomenon, present at the time, also disappeared and analgesics were no …

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentAzathioprineImmunosuppressionGeneral Medicinemedicine.diseaseGastroenterologyThrombosisTransplantationMonckeberg ArteriosclerosisMethylprednisoloneInternal medicineArterial Occlusive DiseasesmedicinebusinessKidney transplantationmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic L…

2009

Abstract Abstract 3351 Poster Board III-239 Objectives: The majority of patients with chronic lymphocytic leukemia (CLL) who receive allogeneic hematopoietic cell transplantation (HCT) have fludarabine-refractory disease. The most active single agent in this disease stage is alemtuzumab. Alemtuzumab has a long half-life and induces profound T-cell depletion (TCD). Since TCD may mitigate graft-versus leukemia effects we evaluated „pre-conditioning“ with alemtuzumab followed by a washout period in order to minimize in vivo T-cell depletion of the graft in a phase II study (NCT 00337519). Methods: Patients received cytoreductive treatment with 3 × 30 mg alemtuzumab weekly prior to HCT. The sch…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaImmunologyCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryFludarabineTransplantationInterquartile rangeInternal medicinemedicineAlemtuzumabbusinessProgressive diseaseBusulfanmedicine.drugBlood
researchProduct

GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in pati…

2019

Summary Background We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report unpubl…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentContext (language use)HematologyHematopoietic stem cell transplantationTotal body irradiation3. Good healthAnti-thymocyte globulinTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineClinical endpointCumulative incidencebusinessBusulfan030215 immunologymedicine.drugThe Lancet Haematology
researchProduct

Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sib…

2009

Abstract Abstract 876 Background: Transplantation of bone marrow (BM) from a HLA-matched sibling donor is an effective treatment for severe aplastic anemia (AA) with long-term survival in excess of 80%. In the recent years there were two trends in allogeneic stem cell transplantation (SCT) for AA: (1) increasing proportion of transplants performed from matched unrelated donors (MUD) and (2) increasing proportion of transplants using peripheral blood progenitor cells (PBSC) as stem cell source instead of BM. A similar switch to PBSC over BM grafts is reported in leukemia transplants. PBSC grafts for leukemia are associated with higher rates of chronic graft-versus-host disease (cGVHD). This …

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyHazard ratioImmunosuppressionCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationLeukemiasurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureInternal medicineparasitic diseasesmedicineBone marrowAplastic anemiabusinessBlood
researchProduct

Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute…

2009

Abstract Abstract 3352 Poster Board III-240 Allogeneic HSCT is established as a potent curative therapy in adult patients with high risk ALL. However, due to transplant-related morbidity and lethality the gains in relapse prevention do not necessarily translate into survival advantages in the overall patient population. Defining the role of allogeneic HSCT in ALL patients in first complete remission (CR1) according to leukemia related risk factors, to transplant related risk factors (e.g. HLA matching, conditioning therapy and immunosuppressive treatment), and to comorbidity related risks, remains a major task for upcoming clinical trials. Several retrospective studies suggest that the HCT-…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologyRetrospective cohort studyCell BiologyHematologyHematopoietic stem cell transplantationTotal body irradiationmedicine.diseaseBiochemistryComorbidityFludarabineSurgeryTransplantationhemic and lymphatic diseasesInternal medicinemedicineCumulative incidenceProspective cohort studybusinessmedicine.drugBlood
researchProduct

2020

Introduction: Renal transplant recipients have a high peri-operative risk for cardiovascular events. The post-transplantation period also carries a risk of myocardial infarction (MI). Coronary artery disease (CAD) is a leading cause of death in these patients. We aimed to assess the risk of MI, the specific morbidity profile of MI after transplantation as well as the long-term prognosis after MI in renal transplantation (RT) patients regarding cardiovascular (CV) death and all-cause death. Methods: From a French national medical information database, all of the patients seen in French hospitals in 2013 with at least 5-years follow-up were retrospectively identified and patients without tran…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentIncidence (epidemiology)030232 urology & nephrologyGeneral Medicine030204 cardiovascular system & hematologymedicine.diseaseCoronary artery diseaseTransplantation03 medical and health sciences0302 clinical medicineInternal medicinemedicineMyocardial infarctionComplicationbusinessDialysisKidney transplantationCause of deathJournal of Clinical Medicine
researchProduct

Radiologic Evaluation of the Transplant Candidate

2003

Before a patient is placed on the waiting list for liver transplantation, a variety of screening procedures are performed, including laboratory tests and radiological procedures. One goal is to search for abnormalities that preclude liver transplantation. Another is to detect abnormalities that in some way will affect the operative procedure. The individual periopera- tive risk is evaluated by searching for pulmonary, cardiac, and renal changes.

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentPortal veinSplenic arteryLiver transplantationmedicine.diseasePortal vein thrombosisWaiting listRadiological weaponmedicine.arteryRadiologic EvaluationmedicineRadiologybusinessScreening procedures
researchProduct

Case report of a large cephalic vein aneurysm inducing heart failure in a renal transplant patient with radio-cephalic fistula for haemodialysis

2020

Highlights • The venous aneurysm is one of the most common complications of autologous AVF. • The vein aneurysm should be treat by surgical resection and anastomotic ligature. • AVF shouldn’t be ligated from 1-year kidney transplantation except in some cases. • Surgical ligation to prevent complications could be considered an option.

medicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesFistulaArteriovenous fistulaCase ReportHeart failure03 medical and health sciences0302 clinical medicineAneurysmmedicinecardiovascular diseasesVeinKidney transplantationArteriovenous fistulaCephalic veinbusiness.industryRenal transplantationmedicine.diseaseSurgeryTransplantationmedicine.anatomical_structure030220 oncology & carcinogenesiscardiovascular system030211 gastroenterology & hepatologySurgerybusinessKidney diseaseSurgical repairInternational Journal of Surgery Case Reports
researchProduct